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Mucosal surfaces account for the vast majority of HIV transmission. In adults, HIV 
transmission occurs mainly by vaginal and rectal routes but rarely via oral route. By 
contrast, pediatric HIV infections could be as the result of oral route by breastfeeding. 
As such mucosal surfaces play a crucial role in HIV acquisition, and spread of the virus 
depends on its ability to cross a mucosal barrier. HIV selectively infects, depletes, and/
or dysregulates multiple arms of the human immune system particularly at the mucosal 
sites and causes substantial irreversible damage to the mucosal barriers. This leads to 
microbial products translocation and subsequently hyper-immune activation. Although 
introduction of antiretroviral therapy (ART) has led to significant reduction in morbidity and 
mortality of HIV-infected patients, viral replication persists. As a result, antigen presence 
and immune activation are linked to “inflammaging” that attributes to a pro-inflammatory 
environment and the accelerated aging process in HIV patients. HIV infection is also 
associated with the prevalence of oral mucosal infections and dysregulation of oral 
microbiota, both of which may compromise the oral mucosal immunity of HIV-infected 
individuals. In addition, impaired oral immunity in HIV infection may predispose the 
patients to periodontal diseases that are associated with systemic inflammation and 
increased risk of cardiovascular diseases. The purpose of this review is to examine 
existing evidence regarding the role of innate and cellular components of the oral cavity 
in HIV infection and how HIV infection may drive systemic hyper-immune activation in 
these patients. We will also discuss current knowledge on HIV oral transmission, HIV 
immunosenescence in relation to the oral mucosal alterations during the course of HIV 
infection and periodontal disease. Finally, we discuss oral manifestations associated with 
HIV infection and how HIV infection and ART influence the oral microbiome. Therefore, 
unraveling how HIV compromises the integrity of the oral mucosal tissues and innate 
immune components of the oral cavity and its association with induction of chronic 
inflammation are critical for the development of effective preventive interventions and 
therapeutic strategies.
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iNTRODUCTiON
HIV infection continues to be a major global health issue with 
an estimated 36.7 million people living with HIV worldwide (1). 
Sadly, 1.1 million people died of HIV or HIV-related comor-
bidities in 2015 alone (1). The development of antiretroviral 
therapy (ART) in 1995 was a significant step in the fight against 
HIV and because of ARTs, HIV no longer is a death sentence 
(2). However, HIV-infected individuals successfully treated 
with ART do not achieve normal longevity, as the viral replica-
tion is suppressed but not completely eliminated (3–6). Long-
term HIV infection, even in the presence of ART, is associated 
with an accelerated onset of non-HIV-related comorbidities 
typically related to aging, including cardiovascular diseases 
(CVDs), osteoporosis, cancer, neurocognitive impairment, 
metabolic disorders, and frailty (7–9). Viral persistence in the 
face of therapy has been explained by, viral latency, lowered 
effectiveness of drugs in some anatomical sites and cell types, 
and cell-to-cell spread of the virus (4). As a result, antigen 
presence due to HIV infection represents the major factor in 
the induction of inflammation and immune activation, both 
of which are linked to “inflammaging” (4, 10). This concept 
attributes to a pro-inflammatory environment and the aging 
process.
The persistence of immune activation and a pro-inflammatory 
environment is in part thought to be due to the leakiness of the 
gastrointestinal (GI) tract (4, 6). The GI tract is an important site 
of HIV pathogenesis and, early in the disease, associated with 
massive depletion of CD4+ T cells, causing irreparable destruc-
tion of the epithelial lining and damage to the immunological 
compartments of the GI tract (11, 12). Among CD4+ T-cells, T 
helper 17 (Th17) cells mediate immunity against pathogens at 
mucosal surfaces; their depletion from the gut of HIV-infected 
individuals increases intestinal permeability and leads to micro-
bial translocation (13). Thus, systemic translocation of the GI tract 
microbial products is thought to directly stimulate the immune 
system and exacerbate inflammation associated with non-AIDS 
comorbidities (14). Microbial translocation in HIV-infected indi-
viduals has been linked to preferential depletion of lymphocytes 
capable of producing the effector cytokines: IL-17 and IL-22 
(4, 14, 15). It is unclear as to why the gut mucosa fails to recover 
even after the commencement of ART. Since the gut-associated 
lymphoid tissue (GALT) is so similar in structure and in resident 
immune cells to the mucosal-associated lymphoid tissue of the 
oral cavity (16), it could be hypothesized that HIV infection may 
result in the induction of similar patterns of destruction in the 
oral mucosal tissues. Oral mucosal immune cells express a wide 
range of pathogen-recognition receptors (PRRs) and metabolic 
sensors that act either as suppressors or activators (17). It is 
unclear whether immunological changes following HIV infection 
compromise the integrity of physical barrier in the oral cavity and 
enhance microbial products translocation, which subsequently 
contribute in the induction of chronic inflammation. Perhaps it is 
possible to propose a relationship between chronic inflammation 
of the oral cavity, such as periodontal disease, and systemic hyper-
immune activation that has been linked to accelerated aging in 
HIV-infected individuals.
Periodontal disease is common among adults and character-
ized by chronic inflammation of the oral mucosa. This disease is 
caused by the interplay between the pathogenic microorganisms 
and host defense that can lead to microbial translocation and 
increased risk of inflammatory conditions, such as CVD (18, 19). 
Studies have shown that between 50 and 70% of adults will be 
diagnosed with periodontal disease during their lifetime (20, 21). 
The prevalence of periodontal disease may result in serious oral 
inflammatory conditions in general, and particularly for immu-
nocompromised individuals (22, 23). It has been shown that 
people living with HIV are simultaneously more likely than their 
HIV-negative counterparts to have serious oral health issues such 
as oral candidiasis, hairy leukoplakia, warts, aphthous ulcers, and 
herpes even in the presence of ART (24, 25). Thus, the potential 
impact of poor oral health in HIV-infected individuals on the 
induction of systemic inflammation, which could be associated 
with accelerated aging needs to be further studied.
Establishing the differences in the cellular and molecular 
components of the innate immunity of the oral cavity between 
HIV-infected and non-infected individuals especially in regards 
to activation markers, expression of PRRs, cytokines, chemokines, 
and host defense peptides (HDPs) may offer new opportunities 
to prevent oral inflammation and subsequently reduce the risk 
of systemic inflammation in this vulnerable population. This 
review focuses on the innate immune components of the oral 
cavity with regard to HIV infection, the key markers associated 
with periodontal disease, the current understanding of oral 
inflammation in HIV infection, as well as evaluates interventions 
that might be utilized to improve oral health of HIV-infected 
individuals.
iNNATe iMMUNe COMPONeNTS OF 
SALivA
The oral cavity is a unique and sophisticated anatomical structure, 
characterized by a combination of soft and hard tissues, which 
is exposed tremendously and constitutively to external stimuli 
(16, 26, 27). As a result, the oral cavity is well served by numerous 
protective innate immune mechanisms. The oral innate immune 
response can be divided into secretory and cellular components. 
For instance, presence of numerous small and large salivary 
glands within the oral cavity protects us from a wide range of 
potential microorganisms that we are constantly exposed to 
through our mouth. Secretory components of the oral cavity 
include IgA, lysozymes, and HDPs such cathelicidins, defensins, 
and histatins are essential for mucosal immunity (Table 1). On 
the other hand, cellular innate immune components of the oral 
cavity are mainly epithelial cells, intraepithelial lymphocytes, 
granulocytes, tissue macrophages, and natural killer cells that 
play a crucial role in oral immunity (28). Dendritic cells (DCs) 
are another cellular components of the oral cavity that constantly 
surveying the area and are mainly found within the oral mucosa 
but can also be detected in the saliva (29, 30). Human saliva con-
tains a vast amount of proteins that each has unique functions. 
Some proteins assist in lubrication or associate with the initiation 
of the digestion process, while others are involved in maintaining 
TABLe 1 | important antimicrobial peptides in the oral cavity.
Antimicrobial peptide Produced by Activity Reference
Secretory IgA • Plasma cells involved in mucosal-
associated lymphoid tissue
• B and T lymphocytes
• Major antibody in saliva
• Inhibits microbial adherence
• Agglutinates bacteria
• Neutralizes virus
(34–37)
Cathelicidins • Neutrophils
• Monocytes
• T cells
• Antifungal, antiviral, antiparasitic
• Broad-spectrum activity against Gram-positive, Gram-negative 
bacteria and HIV
(38–43)
Defensins • Azurophilic granules of neutrophils
• Epithelial cells
• Antimicrobial against Gram-positive and Gram-negative bacteria, 
HIV, mycobacteria, and fungi
• Induce TLR signaling and recruitment/activation of dendritic cells
(17, 38, 40, 44, 45)
Histatins • Component of saliva synthesized by 
parotid and submandibular salivary duct 
cells
• Potent activity against fungi (including Candida albicans)
• Regulate oral hemostasis
• Bond metal ions in saliva
(38, 43, 46)
Lactoferrin • Exocrine glands
• Neutrophils in infected/inflamed sites
• Binds iron
• Bacteriostatic
• Bacteriocidal, anti-HIV
• Decreases biofilm formation
• Decreases reactive oxygen formation
(35, 40, 47–51)
Lysozyme • Present in saliva
• Cytoplasmic granules of macrophages 
and polymorphonuclear neutrophils
• Antibacterial
• Antiviral, anti-HIV
• Binds to and aggregates Gram-positive bacteria
(35, 40, 48, 51)
Secretory leukocyte protease 
inhibitor
• Component of saliva
• Produced by neutrophils, macrophages, 
submandibular glands
• Antiviral, anti-HIV
• Inhibits proteases
• Inhibition of neutrophil elastase
• Bactericidal, antifungal
(40, 52–54)
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homeostasis and combatting pathogenic bacteria (31). Although 
saliva only has about 30% of the proteins normally seen in blood, 
it is commonly being used for diagnostic purposes in different 
conditions (32, 33).
Whole saliva is made up oral fluids from the major and minor 
salivary glands as well as from the gingival crevicular fluid and 
serum transudate from the mucosa (55). It may also contain fluids 
from areas of inflammation, immune and epithelial cells, food 
debris, and microbes (55, 56).
Saliva can be collected with or without stimulation. Saliva that 
is stimulated can have a different pH value when compared to 
unstimulated saliva, as well as has an increased volume of water 
content (55). However, unstimulated saliva can be difficult to 
collect if the individual does not produce a lot of saliva, either 
from dehydration, diet, age, gender, or from the side effects of 
medications (56). In 2010, Miller et al. found that unstimulated 
whole saliva allowed for the identification of several different 
biomarkers that were relevant to the assessment of cardiovascular 
and periodontal disease (55) (Table  2). These biomarkers are 
generally detected at lower levels than found in serum; however, 
there are some that appear at higher concentrations. Common 
detected analytes include tumor necrosis factor (TNF)-α, IL-1β, 
IL-6, fractalkine, growth-regulated oncogene 1-α, and monocyte 
chemotactic protein-1 (55). Elevation of IL-6, osteonectin, IL-1β, 
IL-8, MIP-1α, and MIP-1β in the saliva in acute inflammation 
has been reported and are elevated in the saliva of subjects 
6–9 months prior to detection of bone loss compared to the saliva 
of individuals who remained healthy (57, 58).
There is some concern as to whether salivary proteases may 
degrade cytokines and decrease their ability to be detected; 
however, several studies have shown that the addition of protease 
inhibitors prior to freezing of saliva specimens does not impact 
the levels of detectable biomarkers in the saliva (56, 57). In addi-
tion, it has been reported that these inhibitors may interfere with 
the downstream analytical biomarker assays (84). It has also been 
shown that protein degradation in saliva is a rapid process, and 
the protein breakdown was not affected by the addition of sodium 
azide to the saliva samples (85). Similar observations were made 
following incubation with or without protease inhibitor. For 
instance, the addition of a protease inhibitor reduced detectable 
biomarkers from 26 to 19 compared with saliva samples when no 
inhibitor was added (85). This determines that protein degrada-
tion still occurs even in the presence of inhibitors, and therefore, 
saliva centrifugation and freezing the supernatant at −80°C as 
soon as possible is the best approach for maintaining its integrity 
(56, 84–86).
In addition to their main role in immunoregulation, these 
cytokines and proteins that are produced by infiltrating immune 
cells stimulate local osteoclasts which, in turn, induce alveolar 
bone resorption. Chronic inflammation of the alveolar mucosa is 
initiated by the intricate subgingival biofilm made up of opportun-
istic microorganisms and commensal bacteria (87). In response 
to these pathogens, inflammatory cells and gingival resident cells 
release destructive cytokines and proteinases that can damage 
gingival ligaments and initiate bone resorption (30, 34, 47). For 
example, IL-1β and IL-6 are found to be directly proportional to 
TABLe 2 | Abundant analytes present in oral cavity.
Analyte Activity Levels in saliva Reference
Tumor necrosis factor 
(TNF)-α
• Remodels tissue
• Recruits inflammatory cells
• Initiates bones resorption and inhibits bone collagen 
synthesis
• Increased in patients with chronic periodontitis (55, 59–63)
IL-1β • Induces activation of osteoclasts; resorbs bone
• Synthesized and secreted by fibroblasts, endothelial cells, 
and infiltrating leukocytes
• Elevated levels in patients with increased bone loss
• However, some patients with no evidence of bone loss 
presented with high levels
(55, 57, 58, 64–66)
IL-6 • Produced in infectious or stressed environment
• T and B cell growth
• Activation of osteoclasts
• Increased expression in alveolar bone loss patients (55, 57, 58, 65, 66)
Fractalkine (CX3CL1) • Induces adhesion and migration of leukocytes
• Chemotactic activity for T cells and monocytes
• Increased in periodontal disease
• Upregulated by pathogen-associated molecular 
patterns
(67–72)
CXCL1 • Involved in both inflammation/proliferation
• Attracts neutrophils and induces their degranulation
• May be involved in recruiting lymphocytes during 
diseased state of periodontitis
(72, 73)
Monocyte chemotactic 
protein-1/CCL-2
• Induces chemotaxis of monocytes
• Increases calcium influx
• Stimulates expression of integrins
• Produced by endothelial cells
• Found to increase in patients with periodontal disease, 
mostly in the GCF but can be detected in the saliva as 
well
(63, 74–79)
Osteonectin • Produced by osteoblasts
• Binds calcium in bone in addition to strongly binding 
collagen and hydroxyapatite
• Lower levels in patients with periodontal disease and 
higher levels in patients with healthy bone levels
(57, 80)
IL-8/CXCL-8 • Attracts and activates neutrophils • Increased in patients with chronic inflammation
• Higher than IL-6 and TNF-α
(66, 81)
MIP-1α/1β/CCL-3 • Secreted by inflammatory cells
• Related to cell adhesion and migration
• Stimulates monocytes and osteoclast progenitor cells to 
absorb bone
• Elevated levels in saliva in patients susceptible to bone 
loss
• Elevated in GCF of specific teeth can indicate bone loss
(55, 58, 63, 82, 83)
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bone loss, where osteonectin is inversely proportional to bone 
loss (57). IL-8 is found at higher amounts than IL-6 and IL-1β in 
bone loss patients; however, MIP-1α may be the best biomarker 
to identify periodontal disease (58). In the elderly population, 
these markers will indicate the presence of periodontitis, since 
periodontal disease is more common in aging patients (88–90).
iNNATe iMMUNe COMPONeNTS OF THe 
ORAL CAviTY AND Hiv
HIV infection appears to directly or indirectly impact the sys-
temic and local innate immunity leading to oral opportunistic 
infections and malignancies (91). For instance, higher expression 
of oral cytokeratin in HIV-infected individuals and patients on 
ART has been reported, which indicates transformation of the 
oral mucosa and increased risk of malignancy (92).
As indicated in Figure 1, there are several secretory components 
of saliva that has antiviral and specifically anti-HIV activities. 
These components include cathelicidins, defensins, lactoferrin, 
lysozyme, and secretory leukocyte protease inhibitor (SLPI) 
(38–41, 44, 45, 48, 49, 52–54, 93–95). Cathelicidins are small 
cationic peptides that express antimicrobial activity and found in 
several tissues including the lungs, intestine, mucosa, skin, and 
oral cavity (41). They are predominantly found in the granules of 
neutrophils, mast cells, lymphocytes, keratinocytes, and epithelial 
cells (41). A domain of cathelicidin, LL-37, inhibits HIV replica-
tion in peripheral blood mononuclear cells and is currently being 
evaluated to determine if the same domain inhibits HIV in saliva 
(41, 96). Human β-defensins (hBD) are constitutively expressed 
by oral epithelium and some immune cells and hBD-2 and -3 
are shown to inhibit HIV replication (45). Defensins inhibit HIV 
by directly binding to the virus as well as by downregulating the 
expression of CXCR4 on the cell surface (45). Lactoferrin is an 
iron-binding glycoprotein with strong anti-HIV activity (97). In 
one study, Kazmi et al. incubated whole saliva with an antilacto-
ferrin antibody and determined that there was a reduction in HIV 
inhibition activity by 65% when compared to incubation with an 
IgG control (97). However, the exact mechanism by which lacto-
ferrin inhibits HIV in saliva is still unclear. Lysozyme is another 
components of the saliva with antiviral activity. It is produced by 
the salivary glands, in particular the sublingual salivary gland, as 
well as by neutrophils, macrophages, and is found in the gingival 
crevicular fluids (98). It is speculated that the antiviral activity of 
lysozyme may be due to the degradation of viral polysaccharides 
and RNA transcripts (99). SLPI is a ubiquitous protein produced 
by macrophages, neutrophils, epithelial cells, and the acinar cells 
of parotid, submandibular, and submucosal glands (40). It is 
ambiguous as to how SLPI inhibits HIV infection in the saliva; 
FiGURe 1 | Mechanisms by which salivary inhibitors may disrupt Hiv-1 infection. (1) Virus-specific antibodies (predominantly IgA) neutralize free-floating 
virus. (2) Thrombospondin, acidic proline-rich proteins (PRPs), and polyanionic proteins block cell binding by interfering with gp120 on the virus. (3) Secretory 
leukocyte protease inhibitor (SLPI) and β-defensin disrupt the virion from binding to T cell or macrophage. (4) β-defensin also internalizes and downregulates CXCR4 
coreceptor to deny cellular entry. (5) Mucins and salivary agglutinins bind to gp120 and remove it from the virion making it defective. (6) The hypotonicity of the saliva 
lyses infected cells as well as physically blocking the CD4 coreceptor. (7) Cystatins interfere with proteolytic processes by inhibiting viral cysteine proteases (17, 34, 
44, 101–110).
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however, it appears to involve the host cell instead of binding 
to the virus (53). SLPI may inhibit a step of viral infection that 
occurs once the virus has bound to the cell but before reverse 
transcription occurs (100).
Salivary function and composition are altered with HIV 
infection and some salivary components such as lactoferrin and 
IgA levels are altered in HIV patients with oral candidiasis com-
pared with healthy subjects (111, 112). For example, frequent 
oral infections in HIV patients have been linked to significant 
reduction in lactoferrin and secretory IgA production by parotid 
glands (113).
Thus, innate immune salivary components exhibit a wide 
range of anti-HIV activities; however, any deficiency in their 
secretion and activity may enhance HIV-replication/acquisition 
in the oral cavity.
iMMUNO-PHeNOTYPeS OF THe ORAL 
CAviTY
The oral epithelium provides a physical barrier that protects 
underlying tissues from infection by pathogenic microorganisms 
as well as the effects of environmental threats. The oral mucosa 
is the port of entry into the GI tract where immune homeostasis 
is an important feature of the epithelial lining. The high perme-
ability of the oral mucosa results in consistent contact between 
potentially harmful and harmless antigens with resident immune 
cells (27). As we mentioned earlier, the innate immune cells such 
as macrophages, natural killer cells, polymorphonuclear leuko-
cytes, and DCs are present in the oral cavity and play important 
roles in mucosal immune tolerance (26).
Dendritic cells are professional antigen-presenting cells 
(APCs) that are divided into two subpopulations: myeloid DCs 
and plasmacytoid DCs (26, 114) (Table 3). These two populations 
of DCs differ in their expression of PRRs, in the types of cytokines 
they produce, and their mechanism of activating T cells. Myeloid 
DCs can be further divided into CD1c+ DCs and CD141+ DCs 
(26). A subset of CD11c+ myeloid cells are CD14+, or interstitial 
DCs (114). These DCs are more like monocytes or macrophages 
than conventional CD1c+ or CD141+ myeloid DCs and can 
express CD14+ but do not express costimulatory molecules (114). 
Langerhans cells (LCs), a subset of myeloid DCs, are positive for 
CD11c, MHC-II, as well as CD207 (langerin) (27). Oral LCs are 
positive for all the LC markers as well as CD1a. Oral LCs are 
permanent residents of the basal layer of the oral epithelium and 
TABLe 3 | Classification of dendritic cells (DCs).
DCs Markers expressed Negative 
markers
Reference
Myeloid CD1c+ 
(conventional) DCs
CD1c, CD11b, CD11c, 
CD13, CD33, HLA-DR
CD14, CD16, 
CD19, CD20, 
CD68
(114, 117, 
118)
Myeloid CD141+ 
(conventional) DCs
CD141, CD11c, CD13, 
CD33, HLA-DR
CD11b, CD14, 
CD68
(114, 117, 
118)
• Interstitial DCs CD11c, CD14, CD163, 
CD209, HLA-DR
CD1c, CD141, 
costimulatory 
molecules
(114)
• Langerhans cells CD1a, CD11b, CD11c, 
CD32, CD45, CD80, 
CD86, CD207 (langerin), 
HLA-DR
CD14, CD141, 
CD163, CD205, 
CD209
(29, 114, 
118, 119)
Plasmacytoid DCs CD2, CD7, CD45RA, 
CD68, CD123, CD303, 
CD304, HLA-DR
CD11b, CD11c, 
CD13, CD14, 
CD33
(114, 
117)
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are crucial in maintaining immune tolerance (115). Oral DCs can 
also express costimulatory molecules CD80 (B7.1), CD86 (B7.2), 
and CD40 as markers of activation (27). Plasmacytoid DCs 
generally lack all of the myeloid antigens (114). Identification of 
plasmacytoid DCs in healthy oral tissues has been a challenge, 
but they can be detected in inflammatory conditions in the oral 
cavity (116).
Mucosal DCs are the important component of oral toler-
ance as they have to maintain a homeostatic environment. DCs 
have to initiate a proper immune response against foreign and 
invasive pathogens, while preventing unnecessary activation of 
the immune system in response to commensal bacteria or food 
particles. Resident DCs are found throughout the oral mucosal 
epithelium but are most abundant in the vestibule, buccal 
mucosa, and hard palate (27). The morphology and density of 
DCs are proportional to age and tend to decrease as age increases; 
however, the number of DCs and maturation stage increases in 
the presence of inflammation (120).
While the oral cavity is enriched with APCs due to the abun-
dance of food and microbial antigens, T  cells are seen in very 
low frequency in the saliva and at the oral mucosal surfaces but 
B cells are almost absent in healthy patients. However, in the buc-
cal tissues, CD4+ helper T cells are the dominant cell populations 
followed by CD8+ T  cells and a small percentage of γδ T  cells 
(121). We have already shown that γδ T  cells are abundant in 
the oral cavity and play a protective role against oral candidiasis, 
which is one of the opportunistic fungal diseases associated with 
HIV infection (122). Among these CD4+ T cells, about 10–15% 
of them are Foxp3+, assumed to be T  regulatory cells (Tregs) 
(121). This is important to mention that Foxp3 expression does 
not represent Tregs in human since activated CD4+ T cells may 
also express this marker. High levels of IFN-γ were found to be 
produced by both oral CD4+ and CD8+ T cells, but only 1–2% 
of CD4+ T cells secrete IL-17 (121). However, IL-13 and IL-22 
were not detected in healthy oral mucosa (121). When comparing 
healthy controls to individuals with periodontal disease, it was 
found that CD3+ T  cells remained the largest population; and 
interestingly the B  cell population, which was nearly absent in 
the healthy population, became evident in the individuals with 
periodontal disease (121).
Neutrophils play a crucial role in innate defense as they contain 
and eliminate invading organisms after breaching host anatomical 
barriers, such as the skin and mucosa. Although they are found in 
abundance in the oral cavity of healthy individuals, periodontal 
disease results in a significant increase in CD15+CD16+ neutrophils 
in the oral cavity (121). They are required to ensure homeostatic 
conditions in the oral cavity. A harmonic balance of neutrophils is 
crucial in order to keep bacterial numbers in check as too many or 
too few neutrophils can lead to periodontal tissue damage (123). 
An increase in neutrophils is linked to an upregulation of IL-17, 
which has been shown to be associated with bone loss in animal 
models of periodontal disease (124). Although secretion of IL-17 
is predominantly produced by CD4+ T cells (121), secretion of 
IL-17 by CD4+ T  cells creates a positive feedback loop in the 
area of inflammation as IL-17 promotes neutrophil recruitment 
and also attracts more IL-17-producing CD4+ T cells (123). This 
generates a vicious cycle where inflammation persists indefinitely. 
In addition to the secretion of IL-17 by CD4+ T cells, they also 
produce an array of Th1- and Th2-type cytokines such as IFN-γ, 
IL-6, IL-13, and sometimes IL-10 (125–127). IL-6 and IFN-γ are 
pro-inflammatory cytokines that have been linked to the stimula-
tion of osteoclastic resorption in periodontitis (126–128). IL-10 
and IL-13 are both anti-inflammatory cytokines, which serve to 
inhibit bone resorption (101). This balance of cytokines ensures 
homeostasis of the periodontium; however, when this balance 
is disrupted by pathogens such as Porphyromonas gingivalis or 
Aggregatibacter actinomycetemcomitans, the paradigm can be 
shifted toward a Th1 response and induction of bone resorption 
(126, 128). This indicates that an increase in activated CD4+ 
T cells is associated with bone loss and disease progression.
The innate immune cells are the first line of defense against 
invasive pathogens and rely on a large group of PRRs, which dis-
criminate different pathogens through recognition of conserved 
evolutionary molecular motifs, called pathogen-associated 
molecular patterns (PAMPs) (101). Among the PRRs, TLRs have 
been studied most widely. Upon PAMP engagement, PRRs trig-
ger intracellular signaling cascades eventually culminating in the 
expression of a wide range of pro-inflammatory molecules, which 
together orchestrate the innate immune response to infection, 
and also is a prerequisite for the subsequent induction of adaptive 
immunity (101, 129, 130). TLRs are expressed by various cells 
such as endothelial cells, epithelial cells, gingival fibroblasts, and 
several APCs (101).
Of the 10 TLRs that are known to exist in humans, TLR2 and 
TLR4 are seen most abundantly in the oral cavity (130–133). 
TLR4 recognizes LPS, where TLR2, along with TLR1/TLR6 
recognizes lipopeptides, peptidoglycans, lipotechoic acid, and 
unmodified protein structures (130, 134, 135). Evidence suggests 
that both TLR2- and TLR4-positive cells are upregulated in the 
gingival tissues in periodontitis (17, 130, 131, 133). Binding of 
TLR2 and TLR4 to PAMPs presented on pathogens will induce 
the expression of ICAM-1 and LFA-1 in the oral cavity which can 
lead to downstream bone resorption and increase in the rate of 
periodontitis (101).
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Nucleotide-binding oligomerization domain-like receptors 
(NOD-like receptors) are another member of PRRs. They are 
intracellular sensors that detect PAMPs and endogenous mol-
ecules and can be upregulated similar to TLRs upon stimulation 
by bacterial components (102, 136). They can also sense danger-
associated molecular pattern molecules that are associated with 
cell stress and can induce an inflammatory response in the absence 
of infection (102). NOD1 is ubiquitously expressed within various 
cells such as mononuclear cells, macrophages, DCs, and intestinal 
epithelial cells, while NOD2 is expressed mostly in phagocytic 
cells and intestinal Paneth cells (102, 103). It has been shown that 
NOD1 is involved in the recognition of Gram-negative bacteria 
confirming that this receptor is expressed on epithelial cells since 
these types of bacteria are commonly found to threaten epithelial 
cell linings (104).
Oral epithelial cells constitutively express NOD1 and NOD2, 
which induce the production of antimicrobial products such as 
beta-defensin and peptidoglycan-recognition proteins (105). 
Interestingly, NOD1 and NOD2 do not induce pro-inflammatory 
cytokines when stimulated (106). This may suggest that these 
pattern-recognition molecules on oral epithelial cells actively 
contribute in the removal of bacterial components without initi-
ating an inflammatory response in the oral mucosa (105).
The innate immune cells of the oral cavity are a crucial com-
ponent in protecting underlying mucosal tissues as well as the 
entrance of the GI tract. During homeostasis, these cells work 
together seamlessly to protect the oral mucosa without initiating 
unnecessary inflammatory responses. Disruption of this homeo-
static state by pathogenic bacteria could result in periodontitis 
and subsequently to the translocation of bacterial products into 
the bloodstream that may lead to systemic inflammation and 
potentially CVDs (107, 108). Therefore, any inflammatory condi-
tion in the oral cavity (e.g., periodontal disease) would result in 
the recruitment of different immune cells including HIV-target 
cells into the mucosal sites which may facilitate oral HIV-
transmission. On the other hand, immune deficiency associated 
with HIV infection could impair innate immune responses in the 
oral cavity and predisposes the host to opportunistic infections.
ORAL TRANSMiSSiON OF Hiv
HIV transmission via the oral cavity has been a debatable con-
cept. Multiple studies have failed to isolate the virus in the oral 
epithelial cells, and therefore, absence of virus in the oral cavity 
makes its transmission questionable (24, 28, 91, 137). Therefore, 
it has been thought that the risk of contracting HIV during oral 
sex is very low and antimicrobial peptides, such as human beta 
defensins and SLPI, have been implicated with the low rate of oral 
HIV transmission (138, 139). Orogenital transmission predomi-
nantly occurs via receptive oral sex; however, it seems to be very 
rare (95). The risk of acquiring HIV from receptive oral sex with 
a HIV-positive partner has been estimated to be between 0.04 and 
0.06% (95). Acquiring HIV during receptive anal sex has been 
estimated to be 1.4% and contracting HIV via intravenous drug 
injection has been speculated at 0.63–2.4% (140, 141).
However, the controversy of oral transmission of HIV via 
receptive oral sex is continually examined. Contracting HIV via 
oral sex is difficult to determine because of lack of previous sexual 
history and that oral exposure rarely happens independently of 
other mucosal exposures. Studies investigating oral transmis-
sion of HIV have had small cohorts of high-risk individuals, 
making them insufficient to detect transmission by lower risk 
sexual behaviors (142). In one study, a homosexual couple 
reported engaging in only unprotected oral intercourse, and no 
other form of coition (143). The HIV-negative partner became 
seroconverted through this method; however, it is worth noting 
that this couple had only been sexually active for 1 month and 
it is unclear as to whether the seronegative partner could have 
unknowingly received HIV from a previous partner. Conversely, 
a study from 1990 to 2000 followed a cohort of heterosexual 
HIV-serodiscordant couples to determine if seroconversion 
occurred from unprotected oral intercourse (144). The 135 of 
292 participants who were included in the study used condoms 
for vaginal or anal intercourse but did not use protection for oro-
genital contact. In addition, the participants confirmed that no 
condoms broke or slipped during penetrative intercourse. There 
was over 19,000 unprotected orogenital contacts in the 10-year 
period, looking at both receiving and performing oral sex with 
an infected partner, without a single case of HIV transmission 
occurring (144).
It has been well documented that disrupted, damaged, or 
inflamed oral mucosal tissues impact the risk factor for oral HIV 
transmission (145–147). In fact, there is a higher prevalence of 
contracting HIV through oral intercourse if the partner perform-
ing the act on an HIV-infected individual is a crack-cocaine user 
(146). Oral sores, blisters, and cuts are likely to occur from the 
hot smoke, hot glass or metal pipestem, or from sharp edges of 
the glass pipestem (146).
Although possible to contract HIV through the oral cavity, it 
appears that the oral innate immunity plays an important role in 
preventing the viral infection. This may be due to the protective 
role of the oral mucosa and/or the anti-HIV molecules present in 
saliva. For instance, SLPI is a protein found in mucosal secretions 
originating from submucosal glands and epithelial cells lining 
mucosal surfaces (137). SLPI has been found to have anti-HIV 
properties and disrupt the virus from infecting macrophages 
(53, 54). Furthermore, removal of SLPI in whole saliva in vitro 
was found to decrease its antiviral activity (53). Compared to 
other mucosal secretions in the body including breast milk and 
seminal fluid, saliva has the highest levels of SLPI, where infec-
tious viral levels could not be detected (137).
However, HIV infection impacts expression and secretion of 
oral innate immune molecules. For instance, levels of SLPI in HIV-
infected individuals are found to be decreased (94). In addition to 
SLPI, other oral secretory components including beta-defensin, 
salivary agglutinin, and mucins, thrombospondin, acidic proline-
rich proteins (PRPs), and polyanionic proteins exhibit antimi-
crobial activities (52, 95). Beta-defensin blocks HIV replication 
by directly interacting and blocking virion activity as well as by 
exerting a chemokine-like effect on CD184 (CXCR4) causing 
this coreceptor to internalize and downregulate (45). CD184 
is one of the coreceptors utilized by the virus for cellular entry 
of CD4+ T cells. Both high- and low-molecular weight mucins 
(MG1, MG2), as well as salivary agglutinins bind to and dislodge 
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the viral envelope glycoprotein, gp120, from virions which form 
defective viral particles that cannot infect host immune cells (93, 
95). Thrombospondin, PRPs, and polyanionic proteins (such as 
albumins) block cell binding by interfering with the interaction 
between the cell and gp120 (95). Other factors of preventing HIV 
transmission may include physical blocking of the virus due to 
the high viscosity or viral lysis from low hypotonicity of saliva 
(148). Even though these antimicrobial factors are important in 
preventing HIV infection in the oral cavity, SLPI is considered 
to be the main factor in saliva to protect against HIV infection 
(53, 137) (Figure 1).
Although adults rarely seem to be infected with HIV via the 
oral cavity, it does appear to be a gateway for infectious HIV 
in postnatal vertical transmission (24). Newborns who are not 
infected in utero could acquire HIV via the oral cavity by ingest-
ing infected vaginal secretions or amniotic fluids during delivery 
(149). In addition, transferring HIV from mother-to-infant via 
breast milk has a risk of about 16% (150). Even if viral RNA 
levels are relatively small, the volume of breast milk consumed 
in a day is quite large and there is repetitive exposure of the oral 
mucosa to the virus and any micro abrasion could facilitate the 
HIV transmission. It is still unclear as to where the transmission 
occurs but studies in neonatal rhesus macaque demonstrated 
that the oral mucosa, tonsils, upper GI tract, and stomach as 
possible targets for simian immunodeficiency virus (SIV) 
transmission (24).
ORAL MUCOSAL iNFeCTiONS AND Hiv 
iNFeCTiON
Oral mucosal infections, such as oropharyngeal candidiasis 
(OPC) or hairy leukoplakia, are commonly seen in HIV-infected 
individuals suggesting compromised oral mucosal immunity 
due to HIV infection (25, 91). In fact, studies have shown that 
70–90% of individuals infected with HIV will develop at least one 
oral manifestation over their lifetime, and that the appearance of 
severe oral mucosal infections can be an indicative of progression 
to AIDS (151, 152). The commencement of ART does not alleviate 
all of these manifestations. For instance, a sixfold increase in the 
rate of human papillomavirus (HPV) infection, more commonly 
known as oral warts, has been reported with the onset of ART 
(153, 154). It is still unclear as to why ART decreases some oral 
lesions but increases others. As we discussed above, Th17 cells 
mediate immunity against pathogens at mucosal surfaces and 
are key players of barrier integrity (155). Th17  cells depleted 
from the gut of HIV-infected individuals can lead to microbial 
translocation and non-AIDS comorbidities. Th17 cells along with 
IL-22 stimulate epithelial cells to produce antimicrobial factors 
to eliminate fungi such as Candida albicans and other bacteria 
by promoting inflammation through induction of inflammatory 
cytokines, chemokines, and recruitment of neutrophils (156). 
Recently, it has been reported that Th17-associated cytokines, 
IL-17 and IL-23, are essential in protection against OPC and 
IL-17-induced neutrophil recruitment plays an instrumental 
role in defense against mucosal candidiasis (157) (Figure  2). 
Therefore, in addition to immunodeficiency due to CD4+ T cell 
depletion, it is possible to speculate that possible elimination or 
impairment of IL-17-producing cells in the oral mucosa in the 
course of HIV infection might be associated with susceptibility to 
OPC and other opportunistic infections. In addition, production 
of reactive oxygen species and nitrogen radicals such as nitric 
oxide (NO) can damage or inhibit the growth of C. albicans and 
in agreement we have shown that NO mediates protection against 
oral infection with C. albicans (122). In the oral cavity, NO is 
produced by endothelia, epithelia, and macrophages as well as 
certain bacteria and by abiotic acidification of nitrite (158). The 
release of NO by these cells limits the proliferation of C. albicans; 
however, in some cases, C. albicans expresses flavohemoglobin 
genes to resist against NO (158). Since NO plays an important 
role against C. albicans in the oral cavity, studying the potential 
effect of HIV infection on NO production and possible mutation 
of flavohemoglobin genes to resist NO in HIV-infected individu-
als merits further investigations.
As discussed above, the most common oral manifestations 
associated with HIV infection are OPC and oral warts. In a study 
of 142 ART naïve and HIV-infected patients, oral candidiasis was 
found to be the most prevalent oral manifestation, followed by 
melanotic hyperpigmentation, and then oral hairy leukoplakia 
(159). Once ART is prescribed, all cases of pseudomembraneous 
candidiasis, oral ulcers, and angular cheilitis are resolved after 
3 months (159). However, oral hairy leukoplakia takes longer to 
respond to the medications but would generally decrease in size 
after the first month with the eventual disappearance by the end of 
5 months (159). It has also been reported that protease inhibitors 
act directly on inhibiting the production and activity of a major 
virulence factor of C. albicans particularly involved in mucosal 
(oral and vaginal) candidiasis of HIV-infected individuals (160, 
161). Generally, it is believed that reconstitution of the patient’s 
immune system, characterized by increased in CD4+ T  cells 
and decline in viral load, results in the decline of opportunistic 
infections such as OPC. However, very few patients experience 
resolution of Kaposi’s sarcoma within the 5-month period post-
ART treatment (159).
In another study conducted on 399 HIV-infected ART-naïve 
patients in India, males were shown to exhibit more oral manifes-
tations over females with a ratio of 1.2:1 (162). Oral candidiasis 
was found in 77% of the subjects as the most prevalent disease. 
Erythematous candidiasis was observed to be twofold higher 
than pseudomembranous candidiasis (162). This is in contrast 
to another study conducted in a cohort of HIV-positive patients 
from the South of India (163). In both of these studies, Kaposi’s 
sarcoma was absent from the list of oral manifestations observed 
(162, 163). This may be due to homosexuality being a possible 
risk factor for Kaposi’s sarcoma, while heterosexual practice is the 
main mode of HIV transmission in Asia (162).
There is a higher probability of acquiring oral manifestations, 
specifically oral candidiasis, if the CD4 count is less than 200/µL, 
and therefore, it has been suggested that when a CD4 count is 
unavailable or unattainable, the presence of oral candidiasis may 
be a positive predictive value of HIV disease progression (154, 
162). It is still unclear as to why oral manifestations resolve so 
quickly when ART is initiated, and even more uncertain why 
HPV gets worse. In addition to the increased prevalence of 
FiGURe 2 | Regulation of Candida albicans growth in a healthy oral cavity versus Hiv-infected oral cavity. In a state of health, T helper 17 (Th17) cells 
secrete IL-17 to induce the parotid gland to secrete β-defensin 2/3 in the saliva. β-defensins inhibit C. albicans growth. IL-17 also binds to IL-17R on oral epithelial 
cells to express CXC chemokines to recruit neutrophils to the oral cavity to also combat C. albicans. Oral epithelial cells, neutrophils, and resident macrophages 
secrete antifungal cytokines and nitrogen species such as nitric oxide (NO) to kill C. albicans. During the HIV infection, HIV infects and eliminates Th17 cells. Thus, 
reduction in IL-17 secretion prevents induction of β-defensins, downregulates CXC chemokines expression, and decreases production of other antifungal cytokines. 
As a result, transition of C. albicans to pathogenic hyphae form occurs.
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oral warts, HIV-positive individuals are experiencing a higher 
risk of developing HPV-associated head and neck squamous 
cell carcinomas and not seeing resolution after commencement 
of ART (164). HIV-seropositive individuals appear to have a 
1.5- to 4-fold increased risk for HPV-associated head and neck 
cancer (164). It is known that the decline of CD4+ T lymphocytes 
causes the HIV-infected person to become highly susceptible 
to various infections including the wide range of opportunistic 
oral manifestations (154, 165). HIV infection may alter local 
cytokine production, impact oral microbiota, and subsequently 
virus-induced alterations in the local immune system can impact 
the mucosal immune response to different oral bacteria. These 
data suggest OPC susceptibility in HIV patients is predominantly 
immune based, whereas susceptibility to oral hairy leukoplakia 
and oral warts may be more associated with factors other than 
mucosal immune function.
Of interest, HIV-infected individuals are at greater risk of 
developing Epstein–Barr virus (EBV)-associated malignancy 
such as non-Hodgkin’s lymphoma (166). However, the potential 
role of oral innate immunity in pathogenesis of EBV-associated 
oral lesions in HIV-infected individuals is unknown and merits 
further investigations.
Hiv AND ORAL MiCROBiOMe
The role of oral microbiota is HIV-infected individuals requires 
further attention as either the disease (HIV) or the treatment 
(ART) may impact diversity and composition of the oral micro-
biome. For instance, it has been shown that elevated viremia 
in untreated patients is associated with significantly higher 
proportions of potentially pathogenic Veillonella, Prevotella, 
Megasphaera, and Campylobacter species than in healthy con-
trols (109). Interestingly, increased prevalence of these potential 
pathogens result in the diminished presence of commensal 
Streptococcus and Veillonella species (109). However, ART-treated 
individuals showed lower colonization in their oral cavity by 
Neisseria flavescens compared with healthy controls (109). 
Another study reported that microbial diversity in the oral cavity 
of HIV-infected individuals was lower than healthy controls, and 
this diversity was further reduced following ART treatment (23). 
By contrast, while the bacterial community composition of oral 
wash specimens was unchanged in HIV-infected compared with 
healthy controls, using a deep sequencing approach, a difference 
in fungal communities was observed (167). A recent study on 
HIV-infected individuals undergoing ART has reported similar 
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oral microbiomes but significant difference in the composi-
tion of the oral cavity microbiota (168). This study found that 
Haemophilus parainfluenza, which has been implicated in 
opportunistic infections, was associated with the HIV-infected 
individuals (168). A most recent study utilizing Microarray and 
pyrosequencing techniques reported a significant difference in 
the prevalence and distribution of the saliva bacterial communi-
ties among HIV-infected individuals before and after initiation 
of ART (169). Interestingly, this study found that Actinomyces, 
Atopobium, and Aggregatibacter genera were significantly differ-
ent from the baseline after ART (169). These evidence suggest 
that there is a shift in the oral microbiome and these changes 
might be associated with HIV infection and/or HIV-treatment 
and other oral manifestations associated with disease. One of the 
main limitations of these studies seems to be the limited number 
of studied subjects. Thus, additional studies on larger cohorts are 
required to better understand the potential role of HIV infection 
and/or HIV treatment of oral of microbiome. In addition, how 
these changes in the oral microbiome can impact on the onset of 
other opportunistic pathogens in the oral cavity.
PeRiODONTAL DiSeASe AND SYSTeMiC 
iNFLAMMATiON
Inflammation has long been recognized as a powerful contribut-
ing factor for systemic conditions, such as CVDs including ath-
erosclerosis, coronary heart disease, and thromboembolic events 
(107, 170–172). Despite the identification of risk factors such 
as diet, smoking, obesity, and low physical activity, CVD is still 
on the rise and attention has turned to other associating factors 
such as inflammation (108). Recently, a large body of evidence 
has shown that common oral infections may play an important 
role in atherosclerosis (170) and an increasingly common chronic 
inflammatory disease that is present in 10–15% of the world’s 
population is periodontitis (173).
Periodontitis is a more advanced form of gingivitis where the 
supporting tissues around the teeth including periodontal liga-
ments and alveolar bone are breaking down (173). Clinical signs 
include deepening of the periodontal pocket surrounding the 
tooth, loss of attachment including the gingival mucosa, which 
will progressively lead to loosening of the teeth and ultimately 
tooth loss. The etiology of periodontitis is generally caused by 
local factors, such as accumulation of dental biofilm from poor 
oral hygiene practices, but can also be a manifestation of certain 
systemic diseases. For example, there is a strong correlation 
between patients who have diabetes mellitus and an increased 
prevalence of severe periodontitis (173). It is not only more com-
mon in these patients but also the progression of periodontitis is 
more aggressive and rapid (173). In addition, individuals infected 
with HIV are more susceptible to developing periodontitis 
because of their compromised immune system. Acute necrotiz-
ing periodontitis can also be a manifestation of a newly infected 
individual with HIV (174). In fact, oral manifestations may be 
present in up to 50% of HIV-infected individuals, and up to 80% 
of those who have progressed to AIDS (174, 175).
Looking at periodontitis from a molecular perspective, it 
appears that the host’s immune system in response to pathogens 
secretes substantial amounts of pro-inflammatory cytokines, like 
IL-1β, TNF-α, and IL-6, along with tissue destructive mediators 
like oxygen intermediates and matrix metalloproteinases (172). 
The oral mucosal epithelial lining begins to ulcerate and forms 
an easy port of entry for microorganisms or their by-products 
into the blood stream (176). Many of these bacteria are Gram-
negative, obligate anaerobes and can colonize at distant sites 
(177). Haraszthy et al. tested 50 samples from patients undergoing 
carotid endarterectomy to determine if any periodontal bacterial 
pathogens were present. Forty-four percent of the specimens were 
positive for at least one periodontal pathogen (177). This suggests 
that oral microorganisms can enter the blood stream and induce 
the development and progression of systemic inflammation that 
may lead to other complications such as CVD.
To further link CVD with periodontitis, specific markers 
have been examined. In a study of 7,735 cases of fatal and non-
fatal coronary heart disease, C-reactive protein (CRP), serum 
amyloid A protein (SAA), and serum albumin were found to be 
associating factors with an increased risk of heart disease (107). 
CRP is produced by the liver and serves as a systemic marker of 
inflammation. In the general population, a CRP level of less than 
1.0 mg/L indicates a low risk for CVD (178). A reading between 
1.0 and 2.9 mg/L is an intermediate risk, and a reading greater 
than 3.0 mg/L is considered high risk (178). A CRP level above 
10 mg/L is considered the threshold of significant inflammatory 
diseases such as cancer, tuberculosis, or an autoimmune disorder 
(179, 180). In another study of 5,552 participants, it was found 
that the mean CRP level was approximately one-third higher in 
subjects that clinically presented with periodontitis than com-
pared to subjects with little or no signs of periodontitis (179). 
Similarly, significant increase in CRP levels was found in patients 
with higher levels of clinical attachment loss and bone loss than 
healthy controls (181). This supports the notion that periodontitis 
is associated with an increased CRP level that has been correlated 
with an increased risk of CVD.
In addition to CRP, it has been reported that SAA proteins are 
also elevated in patients with chronic periodontitis (182). SAA 
proteins are part of the apolipoproteins group produced mostly by 
the liver in response to an acute-phase stimulus like an infection 
(182). A pilot study comparing CRP and SAA levels found that 
both were elevated in periodontitis patients and SAA, along with 
CRP, are valuable markers to identify inflammatory conditions 
in patients (182). Serum albumin is another protein produced by 
the liver and the presence of inflammation will reduce albumin 
concentration by decreasing its rate of synthesis (35). The release 
of inflammatory cytokines, like IL-1, IL-6, and TNF-α during an 
infection or inflammation, can decrease serum albumin levels 
(35). In a longitudinal study of 600 subjects, it was found that 
patients with a serum albumin concentration below 4.0 g/dL had 
significantly higher rates of periodontitis than patients with a 
serum albumin concentration above 4.0 g/dL (35).
As discussed above, patients with periodontitis have higher 
levels of CRP and SAA and lower levels of serum albumin com-
pared with healthy population. Therefore, these patients might 
be more prone to the development of CVD. We suggest that the 
saliva of HIV-infected individuals might have higher levels of 
CRP and SAA and lower levels of serum albumin but this needs 
FiGURe 3 | Proposed mechanisms of oral immune regulation in health versus immune-pathology associated with oral disease and impact of that on 
Hiv acquisition. In a healthy state, the epithelial cells are able to maintain microbial colonization and there is a suppressed immune environment. Gingivitis disrupts 
normal immune homeostasis leading to a switch from a suppressed environment to a pro-inflammatory state. Activated immune cells incite pro-inflammatory 
responses and disturb epithelial tight junctions allowing entry of bacterial products with activation of cells that circulate in the peripheral blood. Once gingivitis has 
progressed to periodontitis, there is complete breakdown of the epithelium allowing microbial products to enter the blood stream and travel systemically. Disruption 
of epithelial tight junctions and immune activation also facilitates HIV acquisition in the oral cavity.
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to be further investigated. Thus, these individuals could be at a 
higher risk of CVD than their non-HIV counterparts because of 
their compromised immune system. Taken together, we propose 
that periodontitis and/or compromised oral immune system 
associated with HIV infection may result in a local inflamma-
tory condition and microbial products translocation that leads 
to systemic inflammation (Figure 3). In addition, periodontitis 
and local inflammation in the oral cavity may facilitate HIV 
acquisition.
Hiv AND iMMUNOSeNeSCeNCe
The term “immunosenescence” was first coined by Dr. Roy Walford 
in 1969 and published in his influential book, “The Immunologic 
Theory of Aging” (183). His work generated the basis for current 
ideas about immunological aging. In 1997, Pommier et al. initi-
ated research on immunosenescence in HIV pathogenesis (184). 
This idea commenced due to the remarkable physiological and 
immunological similarities between HIV-infected individuals 
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and the HIV-uninfected elderly. It has been observed that dur-
ing aging, there is a decrease in T cell renewal coinciding with 
terminally differentiated T cells with shortened telomeres (185). 
These changes may be due to the downstream effects of immune 
activation and inflammation causing an overall compromised 
immune system, eventually leading to immunosenescence. This 
phenomenon has been observed in HIV-infected individuals at 
an early age, possibly due to the inflammatory conditions in the 
GI tract leading to systemic inflammation.
With the introduction of ART, a positive diagnosis of HIV 
is no longer considered a death sentence. Since HIV patients 
are now living longer, it has become more obvious that these 
patients are experiencing accelerated aging (110, 186–189). In 
other words, these individuals are facing complications that are 
observed within the elderly population but apparent in a much 
younger age. They experience non-AIDS related comorbidities, 
such as cancer, liver and kidney failure, osteoporosis, CVD, as 
well as neurocognitive decline (189).
One of the features of aging is a depletion in T cell regeneration 
in addition to terminally differentiated T cells with shortened tel-
omeres (185). It is believed that these changes are due to immune 
activation and inflammation, leading to a general decline of the 
immune responses which, eventually translates to immunose-
nescence (190). A common feature in all of these complications 
is chronic inflammation which is a hallmark of age-associated 
comorbidities, as chronic inflammation and immune activation 
are common features of HIV disease.
The intestinal mucosal tissue is the initial site of HIV replication 
and acute phase of infection is associated with the vast depletion 
of CD4+ T cells in the gut due to either direct killing by the virus, 
or due to CD4+ T cells apoptosis (9, 191, 192). Unless ART is com-
menced, the loss of CD4+ T cells continues throughout the entire 
disease course (15). Elimination of CD4+ T cells, including Tregs 
and Th17 cells in the gut results in impairment of the mucosal 
immune system and the disruption of the GI immune functions 
(4, 193). Historically, it is observed that HIV-infected individuals 
experience lymphocyte depletion, malabsorption, and abnor-
malities of the GI mucosal function (14, 15). Vast changes in the 
immune system additionally lead to the loss of naïve and memory 
T cell pool, resulting in a disproportion of T cell phenotypes. This 
altered state of T cells can impair the homeostatic and regulatory 
state of the GI tract.
Once an individual is infected with HIV, the immune activa-
tion associated with the viral replication results in damage to 
the epithelial lining of the intestinal mucosa because the GALT 
contains the majority of CD4+ T  cells in the body. The virus 
breaches the intestinal lining of the lamina propria to target 
and activate CD4+ T cells, macrophages, monocytes, and other 
lymphocytes (194). The activation of the lymphocytes in the gut 
and the immune response to the virus alters the physical barrier 
of the epithelial cells (9). The tight junctions of the epithelial cells 
become inflamed, and the spaces between the epithelial cells 
become permeable (15). This damage also includes the atrophy or 
blunting of intestinal villi and crypt hyperplasia (15, 195). Once 
this occurs, translocation of microbes and their by-products into 
the lamina propria from the lumen exacerbate inflammation by 
translocation of microbial products into the periphery (9, 15). 
The microbial by-products, such as LPS, flagellin, and CpG DNA, 
induce strong pro-inflammatory responses by activating NODs 
and TLRs (9). In turn, these directly stimulate peripheral mac-
rophages and DCs to secrete large amounts of pro-inflammatory 
mediators such as IL-1β, IL-6, and TNF-α (189, 196). Once ART 
is initiated, these cytokine levels decline, indicating that active 
HIV replication is indirectly or directly related to this profound 
inflammatory response (189).
In addition, the gut-associated pathological alterations in 
HIV-infected individuals results in reduction of IL-17 and IL-22 
(14, 15, 197). IL-17 and IL-22 are responsible for maintaining 
mucosal homeostasis in the GALT but severely compromised 
upon SIV infection (197). Thus, quantitative loss of Th17 and 
Th22 CD4+ T-cells has been reported to be associated with 
microbial translocation, systemic immune activation, and disease 
progression (197). Unfortunately, initiation of ART does not fully 
restore the functionality and reconstitution of these mucosal 
Th17, Th22, and Th17/Th22 T-cells (197). In addition to Th22, 
a subset of gut innate immune cells that express natural killer 
cell markers referred to as NK-22 provide an innate source of 
IL-22 and are present in murine mucosa-associated lymphoid 
tissues and appear in the small intestine lamina propria during 
bacterial infection (198). Therefore, these innate lymphoid cells 
(ILCs) are found in mucosa-associated lymphoid tissues and in 
lamina propria as another source of IL-17 and IL-22 (198). ILCs 
play fundamental roles in response to infection by producing 
and secreting cytokines essential for immune regulation, tissue 
homeostasis, and repair (198). These adaptive lymphoid cells 
produce several T cell-associated cytokines, but do not express 
several cell-surface markers commonly seen on other immune 
cell lineages (199). ILCs do not express a T cell receptor and thus, 
fail to respond to antigen (199). It appears that ILCs play a role 
in HIV pathogenesis since ILCs are depleted in the periphery 
of HIV-infected individuals at early stages of the disease in the 
absence of ART (200). It does not appear that ILCs are reconsti-
tuted if ART is commenced during chronic infection, but deple-
tion of the ILCs can be avoided if ART is initiated during the acute 
stage of infection (200). However, currently there is no report on 
oral mucosal ILCs in HIV-infected individuals and whether HIV 
infection results in depletion of these cells in the oral mucosal as 
observed in the gut needs to be investigated.
Although depletion of IL-17 and IL-22 is correlated with the 
extent of microbial translocation, long-term non-progressors and 
elite controllers are shown to avoid microbial translocation and 
maintain good levels of CD4+ T cells including Th17 cells with 
low levels of CD4+ T cells activation in the gut (197, 201).
CONCLUDiNG ReMARKS
HIV infection could be considered a mucosal disease of the GI 
tract. The host’s immune response at the mucosal surfaces is a 
key determinant for HIV acquisition and spread. Thus, compro-
mised mucosal barriers integrity not only facilitates HIV infec-
tion but also translocates microbial products into the periphery, 
resulting in hyper-immune activation. Oral mucosal immunity 
is alerted during HIV infection, as a result this dysregulated 
and/or impaired mucosal barrier may predispose the patient to 
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opportunistic infections and systemic inflammation. The studies 
discussed here evaluate the current knowledge of secretory and 
cellular components of the mucosal surfaces and their role on 
HIV pathogenesis. In addition, HIV oral transmission in both 
infants and adults are discussed and the potential association 
of periodontal disease with HIV and other opportunist infec-
tions are analyzed. Understanding immunological changes at 
the mucosal compartments, in particular in the oral cavity of 
HIV-infected individuals in the presence or absence of ART, 
may assist us to develop novel interventions that may reduce 
mucosal-associated inflammation. However, further studies are 
required to determine how the impaired mucosal integrity of oral 
mucosa due to HIV infection can be prevented or restored. It is 
likely that such studies of basic mechanisms of oral mucosal bar-
riers and immunological alterations will be essential to provide 
a foundation for the development of immune therapeutics 
that can effectively prevent mucosal-associated hyper-immune 
activation.
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